These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27463731)

  • 1. Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma.
    Perier-Muzet M; Boespflug A; Poulalhon N; Caramel J; Breton AL; Thomas L; Dalle S
    JAMA Dermatol; 2016 Oct; 152(10):1162-1164. PubMed ID: 27463731
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
    Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
    Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma.
    Boukari F; Dugourd PM; Chassang M; Mondot L; Passeron T; Lacour JP; Montaudie H
    Pigment Cell Melanoma Res; 2017 Mar; 30(2):262-264. PubMed ID: 27885826
    [No Abstract]   [Full Text] [Related]  

  • 4. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
    Devic P; Amini-Adle M; Camdessanché JP; Dalle S
    Eur J Cancer; 2017 Jun; 78():103-104. PubMed ID: 28432982
    [No Abstract]   [Full Text] [Related]  

  • 5. Cobimetinib (Cotellic) for metastatic melanoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):43-4. PubMed ID: 27027689
    [No Abstract]   [Full Text] [Related]  

  • 6. Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment.
    Kouros P; Gerding H
    Klin Monbl Augenheilkd; 2016 Apr; 233(4):488-9. PubMed ID: 27116515
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.
    Urosevic-Maiwald M; Mangana J; Dummer R
    Ann Oncol; 2017 Jul; 28(7):1673-1675. PubMed ID: 28459947
    [No Abstract]   [Full Text] [Related]  

  • 9. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.
    Perier-Muzet M; Thomas L; Poulalhon N; Debarbieux S; Bringuier PP; Duru G; Depaepe L; Balme B; Dalle S
    J Invest Dermatol; 2014 May; 134(5):1351-1358. PubMed ID: 24304815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent melanocytic nevi after Solcoderm therapy: a new cause of pseudomelanoma.
    Goldenhersh MA; Scheflan M; Zeligovsky A
    J Am Acad Dermatol; 1992 Dec; 27(6 Pt 1):1012-3. PubMed ID: 1479081
    [No Abstract]   [Full Text] [Related]  

  • 11. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
    Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
    Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
    [No Abstract]   [Full Text] [Related]  

  • 12. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
    Chen FW; Tseng D; Reddy S; Daud AI; Swetter SM
    JAMA Dermatol; 2014 Nov; 150(11):1209-12. PubMed ID: 25142409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermoscopic changes in melanocytic nevi in patients receiving immunosuppressive and biologic treatments: results of a prospective case-control study.
    Koseoglu G; Akay BN; Kucuksahin O; Erdem C
    J Am Acad Dermatol; 2015 Oct; 73(4):623-9. PubMed ID: 26293825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new paradigm of systemic therapies for metastatic melanoma.
    Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
    J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New hope in metastatic melanoma treatment?].
    Guillot B
    Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
    [No Abstract]   [Full Text] [Related]  

  • 19. Confocal microscopy and dermoscopy for the monitoring of BRAF inhibitor therapy of melanoma skin metastases.
    Ribero S; Marra E; Tomasini CF; Fierro MT; Bombonato C; Longo C
    Br J Dermatol; 2017 Apr; 176(4):1101-1102. PubMed ID: 27515562
    [No Abstract]   [Full Text] [Related]  

  • 20. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
    Mauzo SH; Tetzlaff MT; Nelson K; Amaria R; Patel S; Aung PP; Nagarajan P; Torres-Cabala CA; Diab A; Prieto VG; Curry JL
    Int J Dermatol; 2019 Sep; 58(9):1045-1052. PubMed ID: 29152725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.